Precision BioSciences Advances Gene Editing Therapy for Chronic Hepatitis B Treatment

Precision BioSciences Advances in Gene Editing for Chronic Hepatitis B Treatment

Precision BioSciences, Inc. achieves a significant milestone with the clearance of its first clinical trial application (CTA) for its pioneering gene editing therapy, PBGENE-HBV, designed to combat chronic hepatitis B. This condition currently affects around 300 million individuals worldwide, underscoring the critical need for innovative treatment options. The company's dual modality approach targets the root causes of viral persistence by eliminating cccDNA and deactivating integrated HBV genomes. This strategic method aims to provide an effective solution for patients suffering from this challenging viral infection, positioning Precision BioSciences as a key player in the evolving landscape of gene therapy.

CEO Michael Amoroso emphasizes the urgency of initiating patient dosing for the Phase 1 trial, highlighting the company's commitment to advancing its HBV program. Precision BioSciences is not only focused on the trial in Moldova, the first country to approve the CTA, but is also actively pursuing additional regulatory approvals in other countries to facilitate swift enrollment. This proactive strategy aligns with the company’s goal to expedite the clinical development process, ensuring that patients gain access to potential therapies as soon as possible. The upcoming updates on PBGENE-HBV’s clinical plans, set to be unveiled on November 15, 2024, will provide valuable insights ahead of the American Association for the Study of Liver Diseases (AASLD) conference.

In tandem with its advancements in PBGENE-HBV, Precision BioSciences is preparing to submit an investigational new drug (IND) application for its second program, PBGENE-3243, which targets m.3243-associated mitochondrial disease. The company’s robust preclinical safety data underpins the promise of PBGENE-HBV, demonstrating its ability to effectively target and eliminate hepatitis B cccDNA while preserving human genome integrity. Positive tolerability results from non-human primate studies further bolster confidence in the therapy, paving the way for future developments in Precision's pipeline.

As the company progresses with its innovative gene editing therapies, it continues to address urgent medical needs, exemplified by its focus on chronic hepatitis B and mitochondrial disease. The upcoming clinical trial data throughout 2025 will be closely monitored by the industry, reflecting Precision BioSciences’ commitment to advancing patient care through cutting-edge science.